Wearable nanopatch platforms for real-time miRNA sensing and editing: a vision for next-generation cancer management.

Ameya, KP, Ross, K ORCID: 0000-0003-0252-1152 and Sekar, D (2025) Wearable nanopatch platforms for real-time miRNA sensing and editing: a vision for next-generation cancer management. Medical Oncology, 42 (12). p. 554. ISSN 1357-0560

Text Wearable Nanopatch Platforms for RealTime miRNA Sensing and Editing A Vision for Next Generation Cancer Management.pdf - Accepted Version Access Restricted until 17 November 2026. Download (296kB)

Abstract

Cancer therapy is undergoing an evolution where on-the-spot, adaptable, and fully personalized treatment will soon be in vogue. Central to this progress are microRNAs (miRNAs), which serve as key regulators in cancer biology. Their altered expression profiles not only provide valuable biomarkers enabling early cancer detection but also offer dynamic molecular targets for therapeutic intervention. miRNAs are key regulators frequently used as cancer biomarkers, enabling early detection and timely intervention. Recent advances in wearable biosensing technologies have ushered in innovative platforms such as smart bandages, flexible electronic tattoos, and microneedle arrays that can monitor molecular biomarkers, including miRNAs, directly from interstitial fluid in a minimally invasive way. Emerging therapeutic applications now include wearable miRNA-editing patches that hold promise to correct dysregulated miRNAs at the disease site. This approach moves beyond static, standard treatments toward dynamic and adaptive cancer therapies tailored in real time. This review discusses the scientific basis of miRNA roles in cancer, recent technological breakthroughs in wearable biosensing and gene editing, and key translational challenges-such as biocompatibility, targeted delivery, and regulatory approvals-that must be addressed to realize the potential of truly personalized next-generation cancer therapy platforms.

Item Type:	Article
Uncontrolled Keywords:	Biosensor; Cancer; Diagnosis; Therapeutics; miRNA; miRNA editing; Humans; MicroRNAs; Wearable Electronic Devices; Neoplasms; Biosensing Techniques; Gene Editing; Biomarkers, Tumor; 32 Biomedical and Clinical Sciences; 3211 Oncology and Carcinogenesis; Cancer; Prevention; Precision Medicine; Bioengineering; Genetics; Biotechnology; 4.1 Discovery and preclinical testing of markers and technologies; Generic health relevance; Cancer; 3 Good Health and Well Being; Humans; MicroRNAs; Wearable Electronic Devices; Neoplasms; Biosensing Techniques; Gene Editing; Biomarkers, Tumor; 1103 Clinical Sciences; 1112 Oncology and Carcinogenesis; Oncology & Carcinogenesis; 3211 Oncology and carcinogenesis
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RS Pharmacy and materia medica
Divisions:	Pharmacy and Biomolecular Sciences
Publisher:	Springer
Date of acceptance:	8 October 2025
Date Deposited:	19 Dec 2025 15:40
Last Modified:	19 Dec 2025 15:40
DOI or ID number:	10.1007/s12032-025-03091-8
URI:	https://researchonline.ljmu.ac.uk/id/eprint/27751

View Item